ChromaDex (CDXC) Competitors

ImmunityBio (NASDAQ:IBRX) and ChromaDex (NASDAQ:CDXC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Does the MarketBeat Community prefer IBRX or CDXC?

ChromaDex received 536 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 64.75% of users gave ChromaDex an outperform vote while only 41.67% of users gave ImmunityBio an outperform vote.

Company	Underperform	Outperform
ImmunityBio	Outperform Votes 15 41.67%	Underperform Votes 21 58.33%
ChromaDex	Outperform Votes 551 64.75%	Underperform Votes 300 35.25%

Which has more risk and volatility, IBRX or CDXC?

ImmunityBio has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, ChromaDex has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.

Which has stronger valuation & earnings, IBRX or CDXC?

ChromaDex has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$14.75M	181.74	-$583.20M	-$0.63	-4.98
ChromaDex	$99.60M	0.00	-$4.94M	$0.10	N/A

Is IBRX or CDXC more profitable?

ChromaDex has a net margin of 1.62% compared to ImmunityBio's net margin of -8,016.83%. ChromaDex's return on equity of 4.85% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-8,016.83%	N/A	-110.02%
ChromaDex	1.62%	4.85%	2.70%

Do analysts recommend IBRX or CDXC?

ImmunityBio currently has a consensus price target of $12.19, suggesting a potential upside of 288.14%. ChromaDex has a consensus price target of $9.03, suggesting a potential upside of 0.00%. Given ImmunityBio's higher possible upside, research analysts clearly believe ImmunityBio is more favorable than ChromaDex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
ChromaDex	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to IBRX or CDXC?

In the previous week, ImmunityBio had 3 more articles in the media than ChromaDex. MarketBeat recorded 6 mentions for ImmunityBio and 3 mentions for ChromaDex. ChromaDex's average media sentiment score of 0.93 beat ImmunityBio's score of 0.76 indicating that ChromaDex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ChromaDex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in IBRX or CDXC?

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 15.4% of ChromaDex shares are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 9.6% of ChromaDex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

ChromaDex beats ImmunityBio on 12 of the 16 factors compared between the two stocks.